Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free PTPI Stock Alerts

Petros Pharmaceuticals (PTPI) Competitors

Petros Pharmaceuticals logo
$0.0028 0.00 (-12.50%)
As of 10/14/2026 11:36 AM Eastern
Compare

PTPI vs. CNSP, IMCC, SRNE, AMPE, and PRPH

Should you buy Petros Pharmaceuticals stock or one of its competitors? Petros Pharmaceuticals's main competitors and comparable companies include CNS Pharmaceuticals (CNSP), IM Cannabis (IMCC), Sorrento Therapeutics (SRNE), Ampio Pharmaceuticals (AMPE), and ProPhase Labs (PRPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CNS Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
CNS Pharmaceuticals N/A -204.25%-141.87%

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A
CNS PharmaceuticalsN/AN/A-$15.85M-$23.59N/A

Petros Pharmaceuticals has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.1, meaning that its stock price is 210% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.39 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
CNS Pharmaceuticals Positive

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to IM Cannabis?

Petros Pharmaceuticals (NASDAQ:PTPI) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, IM Cannabis had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 3 mentions for IM Cannabis and 0 mentions for Petros Pharmaceuticals. IM Cannabis' average media sentiment score of 0.16 beat Petros Pharmaceuticals' score of 0.00 indicating that IM Cannabis is being referred to more favorably in the news media.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
IM Cannabis Neutral

Petros Pharmaceuticals has a beta of 1.87, indicating that its stock price is 87% more volatile than the broader market. Comparatively, IM Cannabis has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

IM Cannabis has higher revenue and earnings than Petros Pharmaceuticals. IM Cannabis is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A
IM Cannabis$45.80M0.01-$8.10M-$60.66N/A

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of IM Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IM Cannabis
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Petros Pharmaceuticals has a net margin of 0.00% compared to IM Cannabis' net margin of -39.62%. IM Cannabis' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
IM Cannabis -39.62%N/A -58.32%

Summary

Petros Pharmaceuticals and IM Cannabis tied by winning 7 of the 14 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Sorrento Therapeutics?

Petros Pharmaceuticals (NASDAQ:PTPI) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Petros Pharmaceuticals has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Sorrento Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
Sorrento Therapeutics N/A N/A N/A

Petros Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A
Sorrento Therapeutics$60.32M0.00-$572.84MN/AN/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
Sorrento Therapeutics Neutral

Summary

Petros Pharmaceuticals beats Sorrento Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Ampio Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Petros Pharmaceuticals has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its share price is 496% more volatile than the broader market.

12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ampio Pharmaceuticals' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
Ampio Pharmaceuticals N/A N/A N/A

Petros Pharmaceuticals has higher revenue and earnings than Ampio Pharmaceuticals. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A
Ampio PharmaceuticalsN/AN/A-$8.63M-$11.01N/A

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Ampio Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
Ampio Pharmaceuticals Neutral

Summary

Petros Pharmaceuticals beats Ampio Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to ProPhase Labs?

Petros Pharmaceuticals (NASDAQ:PTPI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Petros Pharmaceuticals has higher revenue and earnings than ProPhase Labs. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.02-$8.16M-$0.36N/A
ProPhase Labs$5.06M0.04-$53.36M-$2.25N/A

Petros Pharmaceuticals has a beta of 1.87, meaning that its stock price is 87% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market.

Petros Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Petros Pharmaceuticals' return on equity of -78.22% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
ProPhase Labs -825.01%-482.05%-88.90%

In the previous week, ProPhase Labs had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
ProPhase Labs Neutral

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Petros Pharmaceuticals beats ProPhase Labs on 10 of the 12 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTPI vs. The Competition

Export
MetricPetros PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$87K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00631.84198.7718.91
Price / Sales0.02747.00565.6979.10
Price / CashN/A84.0876.6852.75
Price / Book0.009.1510.515.92
Net Income-$8.16M$2.82B$3.50B$380.90M
7 Day PerformanceN/A-4.55%-4.32%-4.38%
1 Month PerformanceN/A-8.50%-8.64%-7.25%
1 Year PerformanceN/A-6.15%2.05%-4.95%

Petros Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTPI
Petros Pharmaceuticals
N/A$0.00
-12.5%		N/A-87.4%$87K$5.11MN/A20
CNSP
CNS Pharmaceuticals
1.0484 of 5 stars		$5.43
+2.5%		N/A-47.5%$7.75MN/AN/A8
IMCC
IM Cannabis
0.185 of 5 stars		$1.90
-2.1%		N/A-97.7%$400K$39.17MN/A44
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-96.0%$245K$60.32MN/A949
AMPE
Ampio Pharmaceuticals
N/A$0.18
flat		N/AN/A$208KN/AN/A6

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel